Vaccines and Public Health
Adult immunization rates are falling short of national targets. Learn how global, federal, and state policies affect vaccination uptake. Leverage our findings to guide your strategies. Rely on our expertise commercializing novel and therapeutic vaccines.
Newborn Screening: Landscape and Rare Disease Developments
Novel approaches to newborn screening of rare diseases could shape the future of federal and state screening guidelines.
Evolving Vaccine Recommendation Landscape Prompts New Evidence Needs
As the processes, priorities, and membership within the ACIP evolve, vaccine manufacturers should adapt their evidence generation planning to support optimal review.
50-State Comparison of Medicaid Adult Vaccine Provider Reimbursement in 2024
A new Avalere analysis reaffirms 2021 findings that first identified variability in Medicaid physician office and pharmacy vaccine reimbursement policies.
eBook: Navigating the Immunization Ecosystem
In this eBook, Avalere experts discuss the evolving vaccines ecosystem and analyze key policy issues affecting vaccines manufacturers.
Adult Seasonal Combination Respiratory Vaccines: Policy Considerations
In a new white paper, Avalere considers key questions related to strain selection, ACIP recommendation, and coverage and reimbursement of adult combination vaccines in development.
Key Policy and Access Themes from the World Vaccines Congress
The World Vaccine Congress addressed the changing landscape of infectious diseases and vaccine types, approvals, recommendations, and reimbursement pathways.
Payment Barriers Persist for Vaccinating Providers
Following policy changes addressing vaccine coverage gaps, stakeholders are focusing on provider financial and administrative barriers to vaccination.
Influenza B Strain Removal Could Impact Future Flu Vaccines
WHO and VRBPAC recommendations to move back toward trivalent influenza vaccines may cause significant shifts in the global flu vaccine landscape.
Guide to Vaccine Coverage Policies
The IRA expanded vaccine access, but variations in federal policies governing vaccine coverage requirements and implementation remain
Therapeutic Vaccines Raise Regulatory, Policy Pathway Questions
In light of the growing therapeutic vaccine pipeline, policymakers are starting to define coverage, access, and reimbursement pathways.
Video: RSV Prevention, Part V: Where Are We Now?
In the fifth installment of our Respiratory Syncytial Virus (RSV) prevention series, Avalere experts discuss updates to the RSV prevention landscape, including newly approved products and recent Advisory Committee on Immunization Practices (ACIP) meeting discussions.
ACIP Contends with Cost, Accessibility, and Equity
At its June meeting, ACIP reviewed data on several currently marketed and novel immunizations, highlighting the committee's focus on cost, accessibility, and equity.
MDRP Proposal Will Impact Vaccine and Novel Immunization Landscape
The proposed vaccine definition would have a significant market impact on novel immunizations such as preventive immunoglobulins and therapeutic vaccines.
Avalere Health Welcomes Emily Lobelo as Vaccine Policy Lead
Emily Lobelo, who has served for 15 years at the CDC, brings extensive knowledge of the vaccine landscape to Avalere’s policy team.
The Future of Water Quality: Half Full or Half Empty?
Lack of running water or indoor plumbing increases morbidity and mortality risk for vulnerable populations.
50-State Comparison of Medicaid Adult Vaccine Provider Reimbursement
A new Avalere analysis identified variability in Medicaid physician office, pharmacy, and Federally Qualified Health Centers vaccine reimbursement policies.
IRA Policy Will Fill Gaps in Medicaid Vaccine Coverage for Adults
Avalere identified 19 states that must change their Medicaid vaccine policies to comply with the IRA’s requirement that states cover all recommended vaccines without cost sharing.
Interview: RSV Prevention, Part IV: Immunocompromised Populations
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
Video: RSV Prevention, Part IV: Immunocompromised Populations
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
Interview: RSV Prevention, Part III: Older Adult Vaccination
Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.